Mid-Afternoon Market Update: Nasdaq Rises 50 Points; Jefferies Shares Drop
Toward the end of trading Wednesday, the Dow traded up 0.05% to 36,269.24 while the NASDAQ rose 0.35% to 15,205.90. The S&P also rose, gaining, 0.26% to 4,725.52.
Mid-Day Market Update: Crude Oil Rises 2%; Philips Shares Plummet
Midway through trading Wednesday, the Dow traded up 0.26% to 36,346.85 while the NASDAQ rose 0.77% to 15,270.07. The S&P also rose, gaining, 0.57% to 4,739.98.
Mid-Morning Market Update: Markets Open Higher; US Inflation Rate Rises To 7% In December
Following the market opening Wednesday, the Dow traded up 0.56% to 36,453.49 while the NASDAQ rose 0.79% to 15,273.08. The S&P also rose, gaining, 0.60% to 4,741.45.
Immuron Shares Rally On US Department Of Defense Funding Of A$6.2M
Immuron Limited (NASDAQ: IMRN) has
Immuron Awarded AU $6.2M to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding of a new research agreement with the U.S Department of Defense.
Immuron Granted European Patent Titled ‘COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ENTERIC BACTERIAL INFECTIONS’
https://data.epo.org/publication-server/pdf-document?pn=3159357&ki=B1&cc=EP
Immuron Announced US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
Immuron Limited (NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on the planned clinical trial program to evaluate the effica